Mycenax Biotech Inc., a biologics CDMO based in Taiwan, has announced strategic alliance with SPERA PHARMA Inc., a Japan-based expert in pharmaceutical Chemistry, Manufacturing, and Controls (CMC).

This collaboration brings together the complementary strengths of both companies to deliver a comprehensive solution for antibody-drug conjugates (ADCs) and bioconjugates, covering linker/payload synthesis, drug substance production, formulation, and aseptic fill-finish, a joint statement by the companies noted.

The alliance aims to accelerate time-to-market for biopharmaceutical companies by offering an integrated and cost-effective ADC development and manufacturing platform. By leveraging Mycenax's end-to-end biologics capabilities with Krisan Biotech and SPERA PHARMA's CMC expertise — particularly in high-potent fill-finish services for ADCs, the partnership delivers a one-stop solution tailored to the needs of global clients.

Founded in 2017 as a spin-off from Takeda Pharmaceutical Company's CMC Research Division, SPERA PHARMA is recognised for its deep experience in complex drug development, including process chemistry, formulation, analytical development, and GMP-compliant aseptic manufacturing.

Mycenax is a global biologics CDMO audited by international regulatory agencies including EMA, PMDA, and Health Canada. Its 2022 strategic partnership with KriSan Biotech further expanded its next-generation ADC technology platform.

Together, Mycenax and SPERA PHARMA offer an end-to-end development and manufacturing solution. This empowers global ADC developers with speed, flexibility, and technical excellence, it said.